EGFR and non-small cell lung carcinoma: For example, in epidermal growth factor receptor (EGFR)-mutant NSCLC, combination of apatinib and gefitinib enhanced the antitumor efficacy in comparison to EGFR-TKIs alone, and delayed the onset of treatment resistance21,22.